Guardant Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helmy Eltoukhy
- Full Time Employees
- 2,498
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3100 Hanover Street Palo Alto CA United States of America 94304
- IPO Date
- Oct 4, 2018
- CIK
- 0001576280
- Website
- guardanthealth.com
- Similar Companies
- Business
- Guardant Health, Inc. is a precision oncology company specializing in blood and tissue-based diagnostic tests, real-world data sets, and AI-driven analytics to enhance cancer detection, treatment, and patient care. Founded in 2012 and headquartered in Palo Alto, California, the company provides a comprehensive portfolio of products including Guardant360 Liquid Biopsy tests (Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response), Guardant Infinity, Guardant Reveal for early-stage cancer, the Shield test for colorectal cancer screening, and GuardantOMNI for biopharmaceutical research. It also offers integrated software solutions like Guardant Connect and research platforms such as Guardant INFORM and Guardant Galaxy. Guardant serves oncology patients, clinicians, and biopharmaceutical companies across the United States and internationally, including direct operations in Asia, the Middle East, and Africa following its full acquisition of Guardant Health AMEA which expanded its reach to 41 countries in those regions. Recent major developments include a strategic multi-year collaboration with Pfizer to leverage Guardant's liquid biopsy technology in global clinical trials and therapeutic development, including access to the Chinese market. The company has advanced its Smart Liquid Biopsy platform with expanded Medicare coverage, notably for its Guardant Reveal and Shield tests, facilitating broader adoption for cancer surveillance and screening. Guardant also completed the full acquisition of Guardant Health AMEA from SoftBank, consolidating its global operations to accelerate market penetration in high cancer burden regions. In 2024, Guardant reported record revenue growth driven by increased reimbursement and volume for Guardant360 assays, and it continues to innovate with new offerings for early detection and therapy response monitoring in multiple cancer indications. This positions Guardant Health as a leading biotechnology firm in precision oncology diagnostics and data analytics worldwide.
Company News
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Reviewing The Pennant Group (NASDAQ:PNTG) and Guardant Health (NASDAQ:GH)
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
Reviewing Guardant Health (NASDAQ:GH) & Privia Health Group (NASDAQ:PRVA)
The Top HealthTech Questions Landing on Our Desks
Reviewing Guardant Health (NASDAQ:GH) & CorVel (NASDAQ:CRVL)
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Guardant Health (NASDAQ:GH) versus InfuSystem (NYSE:INFU) Critical Review
Guardant Health (NASDAQ:GH) Director Sells $144,550.00 in Stock
Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Business Insider Names Guardant Health One of America's Most Innovative Businesses
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer